Cost-effectiveness analysis of screening for first-degree relatives of patients with bicuspid aortic valve.


Journal

European heart journal. Quality of care & clinical outcomes
ISSN: 2058-1742
Titre abrégé: Eur Heart J Qual Care Clin Outcomes
Pays: England
ID NLM: 101677796

Informations de publication

Date de publication:
16 09 2021
Historique:
received: 11 04 2021
revised: 29 06 2021
accepted: 04 07 2021
pubmed: 7 7 2021
medline: 30 3 2022
entrez: 6 7 2021
Statut: ppublish

Résumé

Bicuspid aortic valve (BAV) is the commonest congenital heart valve malformation, and is associated with life-threatening complications. Given the high heritability index of BAV, many experts recommend echocardiography screening for first-degree relatives (FDRs) of an index case. Here, we aim to evaluate the cost-effectiveness of such cascade screening for BAV. Using a decision-analytic model, we performed a cost-effectiveness analysis of echocardiographic screening for FDRs of a BAV index case. Data on BAV probabilities and complications among FDRs were derived from our institution's BAV familial cohort and from the literature on population-based BAV cohorts with long-term follow-up. Health gain was measured as quality-adjusted life years (QALYs). Cost inputs were based on list prices and literature data. One-way and probabilistic sensitivity analyses were performed to account for uncertainty in the model's variables. Screening of FDRs was found to be the dominant strategy, being more effective and less costly than no screening, with savings of €644 and gains of 0.3 QALY. Results were sensitive throughout the range of the main model's variables, including the full range of reported BAV rates among FDRs across the literature. A gradual decrease of the incremental effect was found with the increase in screening age. This economic evaluation model found that echocardiographic screening of FDRs of a BAV index case is not only clinically important but also cost-effective and cost-saving. Sensitivity analysis supported the model's robustness, suggesting its generalization.

Identifiants

pubmed: 34227670
pii: 6316106
doi: 10.1093/ehjqcco/qcab047
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

447-457

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Auteurs

Idit Tessler (I)

Braun School of Public Health and Community Medicine, Faculty of Medicine, The Hebrew University, Jerusalem, Israel.
Heart Institute, Hadassah Medical Center, Jerusalem 91120, Israel.

Moshe Leshno (M)

Faculty of Management and School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Amir Shmueli (A)

Braun School of Public Health and Community Medicine, Faculty of Medicine, The Hebrew University, Jerusalem, Israel.

Shoshana Shpitzen (S)

Heart Institute, Hadassah Medical Center, Jerusalem 91120, Israel.
Faculty of Medicine, The Hebrew University, Jerusalem, Israel.

Ronen Durst (R)

Heart Institute, Hadassah Medical Center, Jerusalem 91120, Israel.
Faculty of Medicine, The Hebrew University, Jerusalem, Israel.

Dan Gilon (D)

Heart Institute, Hadassah Medical Center, Jerusalem 91120, Israel.
Faculty of Medicine, The Hebrew University, Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH